Related Experiment Video
Updated: Feb 28, 2026
Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis
Published on: January 7, 2017
Determination of the binding site of 2-aminothiazole derivative with importin β1 by UV-crosslinking experiment
Siyoung Ha1, Jiwon Oh1, Yong-Hak Kim2
1Department of Chemistry, Chung-Ang University, Seoul 06974, Republic of Korea.
Abstract:
Importin β1 (KPBN1) appears to be overexpressed in several cancer cells and siRNA-induced inhibition of KPNB1 shows significant inhibition of cancer cell proliferation, but do not affect normal cells. These results indicate that KPNB1 is a potential target and inhibition of KPNB1 can be used as a novel therapeutic approach for the treatment of cancer. Recently, we identified the aminothiazole derivative 1 as a KPNB1-targeted anticancer agent. Herein, we report that compound 1 binds strongly to KPNB1, in a pocket centered around serine-476, as shown by UV-crosslinking and tandem mass spectrometry experiments, and supported using a model derived from molecular docking.
Insights
Importin β1 (KPNB1) is overexpressed in cancer cells. Targeting KPNB1 with novel agents like compound 1 offers a promising therapeutic strategy for cancer treatment with minimal impact on normal cells.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Importin β1 (KPNB1) is frequently overexpressed in various cancer types.
- Inhibition of KPNB1 via siRNA reduces cancer cell proliferation without affecting normal cells, suggesting KPNB1 as a viable cancer target.
Purpose of the Study:
- To investigate the therapeutic potential of targeting Importin β1 (KPNB1) in cancer.
- To characterize the interaction of a novel aminothiazole derivative (compound 1) with KPNB1 as an anticancer agent.
Main Methods:
- UV-crosslinking and tandem mass spectrometry were employed to identify the binding site of compound 1 on KPNB1.
- Molecular docking models were utilized to support the experimental binding data.
Main Results:
- Compound 1 demonstrates strong binding to Importin β1 (KPNB1).
- The binding interaction is localized to a specific pocket on KPNB1, centered around serine-476.
- Experimental and computational methods corroborate the binding interaction.
Conclusions:
- The aminothiazole derivative, compound 1, acts as a potent KPNB1 inhibitor.
- Compound 1 represents a novel therapeutic candidate for cancer treatment by targeting KPNB1.
